퓨쳐켐, 3분기 누적 매출 153억원…전년 대비 22.6% 증가
퓨쳐켐은 3분기 누적 매출이 153억원으로 전년 동기보다 22.6% 증가했다고 밝혔다. 회사는 전립선암 치료제 후보물질 FC705의 미국 임상 2a상 주요 결과를 공시했다고 전했다.
Shareholder perspective 실적과 임상 현황 중심의 기사로, 주주권 행사나 지배구조·자본정책 관련 사건은 다루지 않는다.
Use the period buttons above to adjust the range.
Consolidated · includes subsidiaries
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 16.3 × 100M KRW | 30 × 100M KRW | 56.4 × 100M KRW | 81.7 × 100M KRW | 110.1 × 100M KRW | 118.2 × 100M KRW | 125.7 × 100M KRW | 139.7 × 100M KRW | 172.9 × 100M KRW | 186.7 × 100M KRW |
| Operating profit | -38.8 × 100M KRW | -45.3 × 100M KRW | -72.9 × 100M KRW | -53.7 × 100M KRW | -48.7 × 100M KRW | -78.9 × 100M KRW | -129.3 × 100M KRW | - | - | - |
| Net income | -272.9 × 100M KRW | -44.9 × 100M KRW | -120.8 × 100M KRW | -54.9 × 100M KRW | -231.9 × 100M KRW | -34.6 × 100M KRW | -140.1 × 100M KRW | - | - | - |
| Operating margin | -238.98% | -151.02% | -129.29% | -65.72% | -44.22% | -66.80% | -102.87% | - | - | - |
| Balance sheet | ||||||||||
| Total assets | 331.1 × 100M KRW | 360 × 100M KRW | 640.5 × 100M KRW | 632.1 × 100M KRW | 824.6 × 100M KRW | 771.4 × 100M KRW | 887.2 × 100M KRW | 728.3 × 100M KRW | 744.2 × 100M KRW | 745.3 × 100M KRW |
| Total liabilities | 15.8 × 100M KRW | 88 × 100M KRW | 471.7 × 100M KRW | 517.4 × 100M KRW | 388.4 × 100M KRW | 242.2 × 100M KRW | 184.3 × 100M KRW | 89.2 × 100M KRW | 199 × 100M KRW | 197 × 100M KRW |
| Total equity | 315.3 × 100M KRW | 272 × 100M KRW | 168.7 × 100M KRW | 114.7 × 100M KRW | 436.2 × 100M KRW | 529.1 × 100M KRW | 702.8 × 100M KRW | 639.1 × 100M KRW | 545.2 × 100M KRW | 548.3 × 100M KRW |
| Cash flow statement | ||||||||||
| Operating cash flow | - | - | - | - | - | - | - | - | -32.1 × 100M KRW | -24.3 × 100M KRW |
| Investing cash flow | - | - | - | - | - | - | - | - | -114.9 × 100M KRW | -8.8 × 100M KRW |
| Financing cash flow | - | - | - | - | - | - | - | - | 119.1 × 100M KRW | 16.7 × 100M KRW |
| Investment indicators | ||||||||||
| ROE | -86.53% | -16.51% | -71.59% | -47.86% | -53.18% | -6.55% | -19.93% | - | - | - |
| Debt-to-equity ratio | 5.00% | 32.35% | 279.59% | 451.09% | 89.05% | 45.77% | 26.23% | 13.95% | 36.51% | 35.93% |
| Separate total assets | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - |
| PER | - | - | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - |
| Detailed accounts | ||||||||||
| Current assets | - | - | 434.9 × 100M KRW | - | - | 371.7 × 100M KRW | - | - | 395 × 100M KRW | 345.6 × 100M KRW |
| Non-current assets | - | - | 205.6 × 100M KRW | - | - | 399.7 × 100M KRW | - | - | 349.2 × 100M KRW | 399.7 × 100M KRW |
| Current liabilities | - | - | 150.3 × 100M KRW | - | - | 102.5 × 100M KRW | - | - | 157.8 × 100M KRW | 146 × 100M KRW |
| Non-current liabilities | - | - | 321.4 × 100M KRW | - | - | 139.7 × 100M KRW | - | - | 41.3 × 100M KRW | 51 × 100M KRW |
| Equity attributable to owners | - | - | - | - | - | - | - | - | 543.8 × 100M KRW | 546.5 × 100M KRW |
| Share capital | - | - | 28.7 × 100M KRW | - | - | 68.2 × 100M KRW | - | - | 110.5 × 100M KRW | 112.1 × 100M KRW |
| Capital surplus | - | - | - | - | - | - | - | - | 1,206.8 × 100M KRW | 1,320.3 × 100M KRW |
| Retained earnings | - | - | -164.6 × 100M KRW | - | - | -483.5 × 100M KRW | - | - | -784.3 × 100M KRW | -896.9 × 100M KRW |
| Non-controlling interests | - | - | - | - | - | - | - | - | 1.4 × 100M KRW | 1.8 × 100M KRW |
ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.
| Holder | Holding ratio | Change in ownership | Reason for filing | Filing date |
|---|---|---|---|---|
| 지대윤 | 14.33% | +0.78% | 무상증자 신주취득, 단순 추가취득/처분, 주식매수선택권 부여, 임원 퇴임, 신주인수권증서 배정 및 매도 | 2026-08-14 |
| Auditor | Type | Term start | Term end | Tenure | D-day |
|---|---|---|---|---|---|
| 김철 | Auditor | - | 2029.03.25 | 9 years | D-853 |
| Name | Position | Category | Age | Term end |
|---|---|---|---|---|
| 지대윤 | 대표이사 | Inside director | Age 71 | D-492 |
| 김철 | 감사 | 감사 | Age 59 | D-853 |
| 길희섭 | 상무이사 | Inside director | Age 54 | D-492 |
| 유영일 | 상무이사 | Inside director | Age 52 | D-855 |
| 마훈 | 이사 | Other non-executive director | Age 51 | D-490 |
퓨쳐켐은 3분기 누적 매출이 153억원으로 전년 동기보다 22.6% 증가했다고 밝혔다. 회사는 전립선암 치료제 후보물질 FC705의 미국 임상 2a상 주요 결과를 공시했다고 전했다.
Shareholder perspective 실적과 임상 현황 중심의 기사로, 주주권 행사나 지배구조·자본정책 관련 사건은 다루지 않는다.